Health Condition 1: T366- Poisoning by, adverse effect of and underdosing of rifampicins
Conditions
Interventions
None listed
Sponsors
Mohd Monish
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients exhibiting symptoms of AT-DIH,after starting ATT Therapy based upon the criteria established by Indian Network For DILI 2. Patients Willing for trial. 3. Patients aged between 20 years to 70 years of age.
Exclusion criteria
Exclusion criteria: 1. Patients having history of other diseases or taking medications which can alter the interpretation of Liver Function Tests. 2. Patients who are chronic alcoholics or have history of any other substance abuse. 3. Patients taking other Hepatoprotective or Hepatotoxic drugs. 4. Patients having secondary dyslipidemia 5. Patients having low levels of Albumin prior to starting ATT Treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relief in Subjective Parameters 1. Utklesha (Nausea) 2. Chardi ( Vomiting) 3. Aruchi (Loss of Appetite) 4. Hridkanthdah (Epigastric Discomfort) 5. Udarshoola (Abdominal Pain)Timepoint: Outcome will be assessed at baseline,1st week,2nd week,3rd week and after completion of treatment at 4th week. Follow up will be done at an interval of 30 days after the commencement of trial ( 2 follow ups in 2 months) | — |
Secondary
| Measure | Time frame |
|---|---|
| Relief in Objective Parameters 1. LFT 2. Lipid ProfileTimepoint: Outcome will be assessed at baseline,1st week,2nd week,3rd week & after completion of treatment at 4th week. Follow up will be done at an interval of 30 days after the commencement of trial ( 2 follow ups in 2 months) | — |
Countries
India
Contacts
Public ContactMohd Monish
Quadra Institute of Ayurveda and Hospital Roorkee
Outcome results
None listed